Compare BNL & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNL | TNGX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.1B |
| IPO Year | 2008 | 2020 |
| Metric | BNL | TNGX |
|---|---|---|
| Price | $17.58 | $22.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $22.50 | ★ $47.09 |
| AVG Volume (30 Days) | 2.8M | ★ 4.5M |
| Earning Date | 10-28-2026 | 11-13-2026 |
| Dividend Yield | ★ 6.90% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $454,138,000.00 | $62,384,000.00 |
| Revenue This Year | $8.96 | N/A |
| Revenue Next Year | $9.71 | N/A |
| P/E Ratio | $29.48 | ★ N/A |
| Revenue Growth | 5.17 | ★ 48.29 |
| 52 Week Low | $16.70 | $7.37 |
| 52 Week High | $23.10 | $34.39 |
| Indicator | BNL | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 42.38 | 44.87 |
| Support Level | N/A | $20.46 |
| Resistance Level | $19.93 | $25.68 |
| Average True Range (ATR) | 0.51 | 1.73 |
| MACD | 0.04 | -0.17 |
| Stochastic Oscillator | 39.35 | 10.99 |
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.